Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Journal of Cardiac Failure
|
December 8, 2023
Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis
Ahmad Masri, Mathew S Maurer, Brian L Claggett, et al.
Journal of Cardiac Failure
|
November 27, 2024
Wearable Accelerometer-Derived Measures of Physical Activity in Heart Failure: Insights From the DETERMINE trials
Kieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
Journal of Neurology
|
August 14, 2024
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
Isabel Conceição, John L Berk, Markus Weiler, et al.
Circulation. Cardiovascular Quality and Outcomes
|
December 25, 2009
An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure
Patricia S Keenan, Sharon-Lise T Normand, Zhenqiu Lin, et al.
Circulation
|
November 5, 2014
Approaches to enhancing radiation safety in cardiovascular imaging: a scientific statement from the American Heart Association
Reza Fazel, Thomas C Gerber, Stephen Balter, et al.
JAMA
|
August 20, 2009
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006
Harlan M Krumholz, Yun Wang, Jersey Chen, et al.
Journal of the American College of Cardiology
|
April 24, 2024
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis
Marc P Bonaca, Deepak L Bhatt, Tabassome Simon, et al.
Lancet (London, England)
|
September 6, 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Deepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, et al.
European Journal of Heart Failure
|
May 30, 2026
Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen
Marianna Fontana, Amrut V Ambardekar, Francesco Cappelli, et al.
Circulation. Heart Failure
|
May 9, 2026
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy
Ahmad Masri, Francesco Cappelli, Margot K Davis, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Journal of Cardiac Failure
|
December 8, 2023
Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis
Ahmad Masri, Mathew S Maurer, Brian L Claggett, et al.
Journal of Cardiac Failure
|
November 27, 2024
Wearable Accelerometer-Derived Measures of Physical Activity in Heart Failure: Insights From the DETERMINE trials
Kieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
Journal of Neurology
|
August 14, 2024
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
Isabel Conceição, John L Berk, Markus Weiler, et al.
Circulation. Cardiovascular Quality and Outcomes
|
December 25, 2009
An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure
Patricia S Keenan, Sharon-Lise T Normand, Zhenqiu Lin, et al.
Circulation
|
November 5, 2014
Approaches to enhancing radiation safety in cardiovascular imaging: a scientific statement from the American Heart Association
Reza Fazel, Thomas C Gerber, Stephen Balter, et al.
JAMA
|
August 20, 2009
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006
Harlan M Krumholz, Yun Wang, Jersey Chen, et al.
Journal of the American College of Cardiology
|
April 24, 2024
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis
Marc P Bonaca, Deepak L Bhatt, Tabassome Simon, et al.
Lancet (London, England)
|
September 6, 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Deepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, et al.
European Journal of Heart Failure
|
May 30, 2026
Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen
Marianna Fontana, Amrut V Ambardekar, Francesco Cappelli, et al.
Circulation. Heart Failure
|
May 9, 2026
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy
Ahmad Masri, Francesco Cappelli, Margot K Davis, et al.
Page
of 7